Patents by Inventor Cécile Orsini

Cécile Orsini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20220409595
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.
    Type: Application
    Filed: May 25, 2022
    Publication date: December 29, 2022
    Inventors: John P. LEONARD, Jean-François DELEUZE, Jean-Michel ITIER, Cécile ORSINI, Gwénaëlle RET-LECUELLE, Sandra VIALE
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20190046509
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.
    Type: Application
    Filed: April 5, 2018
    Publication date: February 14, 2019
    Inventors: JOHN P. LEONARD, JEAN-FRANÇOIS DELEUZE, JEAN-MICHEL ITIER, CÉCILE ORSINI, GWÉNAËLLE RET-LECUELLE, SANDRA VIALE
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20160361301
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.
    Type: Application
    Filed: December 9, 2014
    Publication date: December 15, 2016
    Inventors: JOHN P. LEONARD, JEAN-FRANÇOIS DELEUZE, JEAN-MICHEL ITIER, CÉCILE ORSINI, GWÉNAËLLE RET-LECUELLE, SANDRA VIALE
  • Engineered secreted alkaline phosphatase (SEAP) reporter genes and polypeptides
    Patent number: 7169913
    Abstract: The invention provides a novel reporter gene (mSEAP) capable of being expressed in a mammal for extended periods of time. Nucleic acids encoding the reporter gene, cells and vectors comprising the nucleic acids, and methods of using the reporter gene to identify expression vectors and screen for drug compounds in an animal are also disclosed.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: January 30, 2007
    Assignee: Aventis Pharma SA
    Inventors: Vincent Thuillier, Manping Wang, Cecile Orsini
  • Recombinant adenoviruses, use thereof for preparing AAVS, complementary cell line, and pharmaceutical compositions containing said adenoviruses
    Patent number: 7033826
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: April 25, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Engineered secreted alkaline phosphatase (SEAP) reporter genes and polypeptides
    Publication number: 20030104422
    Abstract: The invention provides a novel reporter gene (mSEAP) capable of being expressed in a mammal for extended periods of time. Nucleic acids encoding the reporter gene, cells and vectors comprising the nucleic acids, and methods of using the reporter gene to identify expression vectors and screen for drug compounds in an animal are also disclosed.
    Type: Application
    Filed: May 28, 2002
    Publication date: June 5, 2003
    Inventors: Vincent Thuillier, Manping Wang, Cecile Orsini
  • Recombinant adenoviruses, use thereof for preparing AAVS, complementary cell line, and pharmaceutical compositions containing said adenoviruses
    Publication number: 20030039634
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Application
    Filed: April 15, 2002
    Publication date: February 27, 2003
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cecile Orsini, Emmanuelle Vigne
  • Viable contaminant particle free adenoviruses, their preparation and use
    Patent number: 6482617
    Abstract: Novel adenovirus-derived viral vectors, the preparation thereof, and their use in gene therapy, are disclosed. In particular, recombinant adenoviruses including an adenovirus genome wherein (i) the E1 region is inactivated, (ii) the genomic organization is modified, and (iii) optional recombination with the producing line genome generates non-viable viral particles, are disclosed.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: November 19, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Patrice Yeh, Michel Perricaudet, Cécile Orsini
  • RECOMBINANT ADENOVIRUSES CONTAINING AN INDUCIBLE PROMOTER CONTROLLING A GENE OF VIRAL ORIGIN
    Publication number: 20020098165
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Application
    Filed: December 19, 1997
    Publication date: July 25, 2002
    Applicant: Rhone-Poulenc S.A.
    Inventors: MICHEL PERRICAUDET, MARTINE LATTA, EDOUARD PROST, PATRICE YEH, CECILE ORSINI, EMMANUELLE VIGNE
  • Recombinant adenoviruses containing an inducible promoter controlling a gene of viral origin
    Patent number: 6420170
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: July 16, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Viable contaminant particle free adenoviruses, their preparation and use
    Publication number: 20010039046
    Abstract: Novel adenovirus-derived viral vectors, the preparation thereof, and their use in gene therapy, are disclosed. In particular, recombinant adenoviruses including an adenovirus genome wherein (i) the E1 region is inactivated, (ii) the genomic organization is modified, and (iii) optional recombination with the producing line genome generates non-viable viral particles, are disclosed.
    Type: Application
    Filed: January 26, 2001
    Publication date: November 8, 2001
    Applicant: Rhone-Poulenc Rorer S.A.
    Inventors: Patrice Yeh, Michel Perricaudet, Cecile Orsini
  • Viable contaminant particle free adenoviruses, their prepartion and use
    Patent number: 6312946
    Abstract: Novel adenovirus-derived viral vectors, the preparation thereof, and their use in gene therapy, are disclosed. In particular, recombinant adenoviruses including an adenovirus genome wherein (i) the E1 region is inactivated, (ii) the genomic organization is modified, and (iii) optional recombination with the producing line genome generates non-viable viral particles, are disclosed.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: November 6, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Patrice Yeh, Michel Perricaudet, Cécile Orsini
  • Method for preparing a recombinant adenovirus genome
    Patent number: 6261807
    Abstract: A novel method for preparing recombinant adenoviruses and the use of such adenoviruses in gene therapy are disclosed. Plasmids used in the construction of said adenoviruses are also disclosed.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 17, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Joël Crouzet, Laurent Naudin, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Defective recombinant adenoviruses with inactivated IVa2 gene
    Patent number: 6200798
    Abstract: The present invention relates to new viral vectors derived from adenoviruses, their preparation and utilization in gene therapy. It relates particularly to defective recombinant adenoviruses wherein the Iva2 gene at least is inactivated.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: March 13, 2001
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Patrice Yeh, Michel Perricaudet, Cécile Orsini, Emmanuelle Vigne
  • Cells for the production of recombinant adenoviruses
    Patent number: 6127175
    Abstract: The invention relates to cells usable for the production of defective adenoviruses comprising, inserted into their genome, a portion of the region E4 of an adenovirus genome carrying the reading phase ORF6 under the control of a functional promoter.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: October 3, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Emmanuelle Vigne, Michel Perricaudet, Jean-Fran.cedilla.ois Dedieu, Cecile Orsini, Patrice Yeh, Martine Latta, Edouard Prost